HC Wainwright & Co. Maintains Buy on Purple Biotech, Raises Price Target to $9
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Emily Bodnar maintains a 'Buy' rating on Purple Biotech (NASDAQ:PPBT) and raises the price target from $7 to $9.
August 30, 2023 | 3:20 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. maintains a 'Buy' rating on Purple Biotech and raises the price target from $7 to $9.
The 'Buy' rating maintained by HC Wainwright & Co. and the increase in price target from $7 to $9 indicates a positive outlook for Purple Biotech. This could potentially lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100